Blue Water Vaccines, Inc. (BWV) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Cincinnati, OH, United States. Der aktuelle CEO ist Neil J. Campbell MA, MBA.
BWV hat IPO-Datum 2022-02-18, 12 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $3.41M.
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
